EKSO Stock Forecast & Price Target

Ekso Bionics Holdings Inc. reported a significant recovery in its financial performance for the third quarter of 2025, with total revenues reaching $4.22 million, marking a 105% quarter-over-quarter growth. Additionally, the company experienced an improvement in gross margins, which increased to 60.3% from 39.8% in the previous quarter. These developments, along with the recent announcement of a non-binding merger agreement, suggest a strong rebound in business operations and potential for future expansion, positively influencing the outlook for Ekso Bionics' stock.

The financial analysis indicates a negative outlook for Ekso Bionics Holdings due to recent underperformance in revenue, which missed consensus expectations by reflecting a softness attributed to order delays totaling $1.5 million. In the third quarter of 2025, the company reported revenues of $4.23 million and a net loss of $0.54 per share, which, while slightly above consensus estimates, still highlights ongoing profitability challenges. Furthermore, the decision to downgrade the company's rating to Neutral and remove the price target suggests a lack of confidence in its ability to achieve meaningful growth in the near term.